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Sucrose loaded model (SLM)Abstract Thiazolidinediones are well known for causing reduction in blood glucose levels. A num-
ber of thiazolidinediones have been approved for clinical use in diabetes. Present research work is
based on the synthesis of thiazolidinedione derivatives that were designed previously using 2D
QSAR for antidiabetic activity. Thiazolidine-2,4-diones derivatives having carboxylic ester append-
ages at N-3 and 5-substituted benzylidene were studied and the syntheses of only four derivatives
were performed that were predicted to have promising antidiabetic activities. Their effect on hypo-
glycemic activity was performed using a sucrose loaded model. Compounds 5a and 5b were found
to have prominent activities at 100 mg/kg by oral route administration.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
According to the American Diabetes Association, the direct
costs in 2007, of treating the estimated 23.6 million type 2 dia-
betes mellitus (T2DM) patients and the estimated 57 million
pre-diabetic patients in the United States was approximately
$116 billion with an additional $58 billion dollars in indirect
costs (Hanrahan et al., 2012). Most cases will be of type 2 dia-
betes, which is strongly associated with a sedentary life style
and obesity. Early stages of type 2 diabetes mellitus (Type II
DM) are characterized by tissue resistance to the effects of
insulin secreted by pancreatic b cells (Rang et al., 2008).From the pioneering discovery of ciglitazone (Defronzo,
2000), a new class of thiazolidinedione based compounds have
been developed to treat diabetic patients that can reverse the
insulin resistance in non-insulin dependent diabetes mellitus
(NIDDM). Among various substituted benzyl-2,4-thiazolidin-
edione compounds, troglitazone (Yoshioka et al., 1989), piog-
litazone (Momose et al., 1991), and rosiglitazone (Cantello
et al., 1994), are potentially antidiabetic compounds that have
been clinically examined. The ﬁrst marketed thiazolidinedione,
troglitazone (Krook et al., 2000), was withdrawn because of
the increased risk of hepatotoxicity (Scheen, 2001). The potent
side effect i.e., hepatotoxicity limits the use of thiazolidine
derivatives as safe drug candidates.
Many drugs have been approved from this class for the
treatment of diabetes like Rosiglitazone, Pioglitazone, Ciglit-
azone and many more. Though the marketed drugs show addi-
tive effect with other antihyperglycemic agents, they are also
prone to show toxicity. For example, Rosiglitazone shows hep-
atotoxicity (Kahn et al., 2006). Hence there is a need to ﬁnd
more potent and orally safe thiazolidine 2,4-diones with less
toxicity.
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Figure 2 Scheme: Reagents: (a) Piperidine, Ethanol, CH3-
COOH; (b) NaH, ethyl bromoacetate, Dry DMF; (c) Conc.
HCl, Glacial acetic acid.
Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents S197In the present research work, we have performed the syn-
thesis of thiazolidinedione derivatives that were designed pre-
viously using 2D QSAR for antidiabetic activity.
Thiazolidine-2,4-diones derivatives having carboxylic ester
appendages at N-3 and 5-substituted benzylidene were de-
signed and the syntheses of only the best four derivatives were
performed that were predicted to have promising antidiabetic
activities.
2. Drug design
We have performed 2D QSAR on the series reported by Bhat
et al. (2004) using software VLife MDS 3.5 in our laboratory.
It gives the output as an equation containing descriptors such
as alignment independent parameters and as an indicative of
physicochemical properties required to show biological activity
i.e., antihyperglycemic activity. The correlation between inde-
pendent variables (descriptors) and dependent variables (phar-
macological activity) was established (Puzyn et al., 2010). The
output is in the form of regression equation showing descrip-
tors are in the form of positive and negative contributions by
using the equation as an output from the QSAR study, we
have designed the following derivatives. And further their
syntheses has been done followed by hypoglycemic activity
using SLM model in rats.
3. Experimental
Derivatives under study as depicted in Fig. 1, shows R1 varied
as either a 5 and 6 membered ring while R2 varied from H,
methyl, or ethyl groups and the derivatives to be synthesized
are based upon substitution on the benzene moiety next to
thiazolidinedione (TZD) ring.
Hypoglycemic study has been done using the animal model
already reported in the literature. The animal model being used
is Sucrose Loaded Model (Godkar and Godkar, 2003), though
other models are available (Chaturvedi et al., 2008; Sharma
et al., 2010; Ram et al., 2003), blood glucose estimation has
been done using a glucometer (Pattan et al., 2009).
4. Chemistry
The synthetic protocol of thiazolidinedione derivatives pre-
sented here is shown in Scheme (Fig. 2). Thiazolidin-2,4-dione
1 (Prashantha et al., 2006) on reacting with benzaldehyde
derivative 2 undergoes Knovengeal condensation giving ben-
zylidene thiazolidinedione 3a–3b (Bruno et al., 2002) which
upon N-Alkylation with ethyl bromoacetate furnished alkyl
2,4-dioxothiazolidin-3-ethyl ester 4a–4b (Goel et al., 2004),
ethyl ester is being converted to acid derivative 5a–5d using
conc. HCl and glacial acetic acid.
Melting points were determined by open capillary tubes
using VEEGO VMP-D Digital melting point apparatus andS
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Figure 1 Thiazolidinediones.are uncorrected. FTIR spectra of the powdered compounds
were recorded using KBr on a JASCO FTIR 4100 series and
are reported in cm1 and 1H NMR spectra were recorded on
a Varian Mercury YH300 (300 MHz FT NMR) spectropho-
tometer using TMS as an internal reference (Chemical shift
represented in dppm). Purity of the compounds was checked
on TLC plates using silica gel G as stationary phase and iodine
vapors as the visualizing agent.
4.1. General procedure for 5-(substituted benzylidene)-2,4-
thiazolidinediones, 3a–3d (Bruno et al., 2002)
A mixture of 2,4-thiazolidinedione 1 (2.4 g, 20 mmol), benzal-
dehyde derivative 2 (20 mmol), piperidine (1.4 g, 16 mmol) and
ethanol (150 ml) was reﬂuxed for 16–24 h. The reaction mix-
ture was poured into H2O and acidiﬁed with AcOH to give
3a–3d as solids, which were recrystallized from methanol.
Completion of reaction has been conﬁrmed using TLC using
Benzene:Ethyl acetate as solvent system (3:7).
4.2. General procedure for [5-(substituted benzylidene)-2,4-
dioxo-thiazolidin-3-yl]-acetic acid ethyl ester, 4a–4b (Bruno
et al., 2002)
Sodium hydride (0.576 g, 24 mmol) was added portion wise to
a solution of 5-benzylidene-2,4-thiazolidinedione 3 (20 mmol)
in dry DMF and the mixture was stirred at 80C for 1.5 h.
The mixture was cooled to room temperature and a solution
of ethyl bromoacetate (3.7 g, 24 mmol) in dry DMF was added
dropwise. After being stirred at 80C for 15–20 h, the reaction
mixture was poured into H2O and the solid product ﬁltered
and recrystallized from EtOH/H2O.
4.3. General procedure for [5-(substituted benzylidene)-2,4-
dioxo-thiazolidin-3-yl]-acetic acid 5a–5d (Bruno et al., 2002)
A mixture of ethyl ester (10 mmol), glacial AcOH (40 ml) and
HCl 12 N (10 ml) was reﬂuxed for 2 h. After evaporation in
Table 1 Elemental analysis (C, H, N).
Compound no. M.P. C % Yield Theoretical value (%) Observed value (%)
C H N C H N
5a 218–220 60 52 4.02 4.33 54.9 5.26 4.70
5b 189–191 65 50.99 4.24 3.96 51.7 5.07 4.02
5c 181–183 57 50.48 3.55 4.53 50.9 4.21 5.12
5d 173–175 52 49.55 3.83 4.12 51.0 4.15 4.78
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Figure 3 The designed thiazolidinedione analogs using 2D
QSAR.
S198 P.A. Datar, S.B. Ahervacuo, the residue was reﬂuxed again with AcOH (40 ml) and
HCl (10 ml) for 2 h. After evaporation to dryness in vacuo, the
crude solid was washed with H2O and recrystallized from
EtOH providing pure carboxylic acid.
For the above steps the yield obtained for each of the se-
lected substituted thiazolidinediones and their physicochemical
properties, and elemental analyses for C, H, N are shown in
Table 1. Following are the spectral data obtained by FTIR
and 1H NMR studies.
4.4. Synthesis of 5-(3,4-dimethoxy)benzylidine-2,4-thiazolidine
dione, (5a)
Benzaldehyde derivative used is Veratraldehyde (3,4-dime-
thoxybenzaldehyde) keeping the other reagents and lab condi-
tions the same. Brownish solid. IR (KBr) v cm1 (C–O) 1301,
(C‚O) 1721, (Ar C–H) 3072, (OH) 3239, (C‚C) 1581. 1H
NMR (DMSO) d 1.2, (s, CH2), 10.8 (s, COOH), 4.45 (s,
C‚C–H), 3.91 (s, O–CH3), 6.8–7.5 (m, Ar–H).
4.5. Synthesis of 5-(3,4,5-trimethoxy)benzylidine-2,4-
thiazolidine dione (5b)
Benzaldehyde derivative used is 3,4,5-Trimethoxybenzalde-
hyde while other reagents and other conditions have been kept
the same. Faint brownish powder. IR (KBr) v cm1 (C–O)
1301, (C‚O) 1721, (Ar C–H) 3072, (OH) 3239, (C‚C)
1581. 1H NMR (DMSO) d 1.2, (s, CH2), 10.8 (s, COOH),
4.48 (s, C‚C–H), 4.1 (s, O-CH3), 6.85–7.5 (m, Ar–H).
4.6. Synthesis of 5-(3-methoxy-4-hydroxy)benzylidine-2,4-
thiazolidine dione (5c)
Benzaldehyde derivative used is Vanillin (3-methoxy-4-hydro-
xy benzaldehyde) while other reagents and conditions have
been kept the same. Faint brownish powder. IR (KBr) v
cm1 (C–O) 1234, (C‚O) 1737, (Ar C–H) 3012, (OH) 3544,
(C‚C) 1600. 1H NMR (DMSO) d 1.2, (s, CH2), 10.8 (s,
COOH), 3.95 (s, O–CH3), 4.5 (s, C‚C–H), 6.95–7.5 (m, Ar
C–H), 1.6 (Ar–OH).
4.7. Synthesis of 5-(3,5-dimethoxy-4-hydroxy)benzylidine-2,4-
thiazolidine dione (5d)
The derivative used is syringaldehyde (3,5-dimethoxy-4-hydro-
xy benzaldehyde) while other reagents and other conditions
have been kept the same. Very dark brown powder. IR
(KBr) v cm1 (C–O) 1249, (C‚O) 1731, (Ar C–H) 3055,
(OH) 3619, (C‚C) 1687. 1H NMR (DMSO) d 1.2, (s, CH2),
10.4 (s, COOH), 3.95 (s, O–CH3), 4.5 (s, C‚C–H), 6.95–7.5
(m, Ar C–H), 1.6 (Ar–OH).5. Biology
5.1. Sucrose loaded model (SLM) (Godkar and Godkar, 2003)
Wistar rats weighing in the range 250–300 g were obtained
from National center for cell science (NCCS), Pune, India.
In this study a group of six male Wistar rats were used per dose
per compound. Animals were housed in standard cages, under
standard ambient conditions, temperature (25 ± 2 C), and
relative humidity of 50 ± 5%. A 12:12 h light: dark cycle
was maintained. All the animals were allowed to have free ac-
cess to water and standard palletized laboratory. The blood
glucose of each animal was checked after 16 h starvation using
glucose strips and glucometer. Animals showing blood glucose
between 135 and 150 mg/dl were selected as suitable for the
test. Dose given is as reported in the literature. Rats of the
experimental group were administered in the form of suspen-
sion of the desired compound orally made in 1.0% gum acacia
for a dose of 100 mg/kg-body weight. Animals of the control
Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents S199group were given an equal amount of 1.0% gum acacia. A su-
crose load of 2.0 g/kg was given to each animal orally initially.
Thirty minutes later to sucrose administration, the test com-
pound was administered orally. After the test compounds are
administered, blood glucose proﬁle of each rat was determined
at 30, 60, 90, and 120 min by using glucose strips and the glu-
cometer. Food but not water was withheld from the cages dur-
ing the course of experimentation. Pioglitazone has been used
as the reference standard during the course of experimentation.
All the experimental procedures and protocols used in these
studies were reviewed and approved by the Institutional Ani-
mal Ethics Committee (IAEC) of College, Pune, constituted
in accordance with the guidelines of the Committee for the
Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Government of India. Animals were
not sacriﬁced during the course of experimentation. Percent-Table 2 Blood glucose levels in experimental animals (mg/dl).
Compound no. Time (min)
0 30
DMSO 145 156
Pioglitazone 139 105
5a 141 112
5b 147 110
5c 133 117
5d 136 114
Table 3 Decrease in blood glucose levels by AUC method.
Compound no. Time (min)
30 60 90
DMSO +11 +05 +02
Pioglitazone 34 39 29
5a 29 25 24
5b 37 35 28
5c 16 18 14
5d 22 17 15
Figure 4 AUC’s of decrease in blood glucose leage hypoglycemic activity has been determined by AUC
method.
6. Results and discussion
As per the 2D QSAR studies performed for the thiazolidined-
ione series in our lab, the following descriptors were used in the
design.
The term T_2_T_6 contributes negatively toward activity,
which signiﬁes the count of any double bonded atom separated
from any atom by a six-bond distance. While T_T_N_5 also
shows a negative contribution toward biological activity,
which signiﬁes the count of any atom (single, double or triple
bonded) separated from any nitrogen atom (single or double
bonded) by a 5-bond distance. Next descriptor we obtained
is the SssCH2 count, which contributes negatively toward60 90 120
150 147 141
110 112 115
117 118 112
112 107 104
115 119 123
119 121 127
% Reduction in blood glucose level
120
04 +3.17
26 23.07
27 21.71
24 22.84
10 10.3
09 10.51
vel for DMSO (control), Pioglitazone, 5a–d.
S200 P.A. Datar, S.B. Aherantihyperglycemic activity; it signiﬁes the total number of –
CH2 group connected with two single bonds. T_T_O_3 is the
next negatively contributing descriptor which determines the
count of any atom (single, double or triple bonded) separated
from any oxygen atom (single or double bonded) by a three-
bond distance. In 2D QSAR equation, a positively contribut-
ing descriptor called the H Count indicates the number of H
atoms in a molecule. The following molecules were designed
as given in Fig. 3.
The design includes strategies such as the selection of sub-
stituents that will have as the maximum part, hydrogen. Func-
tional groups where maximum hydrogen occurs are found as
alkyl and not aryl groups. Tert butyl and secondary butyl,
would be more preferred over n-butyl as primary selection cri-
teria. The virtual molecules were predicted on the basis of 2D
QSAR equation generated. It was required that oxygen should
be at a distance of one or two or larger than three, but not a
three bond distance. In such stringent criteria the methoxy
group would be ideal for substitution. Further negative impact
of the SssCH2 count suggests that CH2 groups should not be
preferred. Thus designed analogs are the composition of the
methoxy group. Replacement of the methoxy group to the hy-
droxyl group has been made to ﬁnd the optimal position of the
methoxy group. The results obtained from the biological study
have been given in following Tables 2 and 3.
It has been seen that Pioglitazone showed a decrease in
BGL in 30 min. while 5a and 5b shows a sudden decrease in
BGL within a span of 30 min, and then a constant decrease ap-
peared. While 5c and 5d showed a decrease in ﬁrst 30 min, but
after that they fail to show a decrease in the blood glucose level
(BGL) and a further increase in BGL has been observed.
Fig. 4 shows a decrease in blood glucose level by the AUC
method w.r.t. a time interval of 30 min. On the X axis, the re-
sponses for 30, 60, 90, 120 min are shown for DMSO (control),
Pioglitazone (standard), and the synthesized compounds (5a–
5d). From the AUC graph, it can be observed that 5a and 5b
showed a maximum reduction and consistent reduction in
blood glucose level for 120 min, while 5c and 5d shows a poor
response of reduction in blood glucose levels.
7. Conclusion
By using 2D QSAR, the physicochemical properties required
for hypoglycemic activity have been used to synthesize new
derivatives. The hypoglycemic activities of 5-substituted ben-
zylidene thiazolidine-2,4-dione-3-acetic acids were evaluated
by the SLM model. The dimethoxy and trimethoxy derivatives
have shown nearly equal hypoglycemic activities comparable
with the standard used Pioglitazone. But when one –OCH3
group of each of the derivatives has been replaced by –OH
group, there is decrease in hypoglycemic activity.Acknowledgement
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